Halozyme Therapeutics, Inc. $HALO Shares Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 264,490 shares of the biopharmaceutical company’s stock after buying an additional 12,438 shares during the quarter. Principal Financial Group Inc. owned approximately 0.22% of Halozyme Therapeutics worth $17,094,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HALO. Norges Bank purchased a new stake in Halozyme Therapeutics during the fourth quarter worth approximately $128,201,000. William Blair Investment Management LLC purchased a new position in Halozyme Therapeutics in the fourth quarter valued at approximately $124,031,000. Voloridge Investment Management LLC acquired a new stake in Halozyme Therapeutics during the third quarter worth approximately $77,587,000. Qube Research & Technologies Ltd acquired a new stake in Halozyme Therapeutics during the second quarter worth approximately $51,295,000. Finally, Mizuho Markets Americas LLC lifted its position in shares of Halozyme Therapeutics by 270.8% during the 4th quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after buying an additional 926,526 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HALO has been the topic of a number of recent analyst reports. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. HC Wainwright reissued a “buy” rating and issued a $95.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday. UBS Group restated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday. Finally, Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total value of $1,435,000.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $55,088,215. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the transaction, the director owned 42,044 shares in the company, valued at approximately $3,225,195.24. This trade represents a 3.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 74,102 shares of company stock worth $5,205,798 in the last three months. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $77.82 on Thursday. The firm has a market cap of $9.23 billion, a P/E ratio of 27.99, a P/E/G ratio of 0.33 and a beta of 0.84. Halozyme Therapeutics, Inc. has a 52-week low of $57.33 and a 52-week high of $82.26. The business’s 50-day moving average price is $72.55 and its 200 day moving average price is $70.43. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same period last year, the firm earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.